ArticleWorld journal of clinical cases2018
Current trends of liver cirrhosis in Mexico: Similitudes and differences with other world regions.
Article in World journal of clinical cases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 57 citations in OpenAlex.
- Noninvasive Evaluation of Prolonged-Release Pirfenidone in Compensated Liver Cirrhosis. ODISEA Study, a Randomised Trial.Liver international : official journal of the International Association for the Study of the Liver · 2025Trial
- From NAFLD to MASLD and MetALD: Conceptual Shifts in Metabolic Liver Disease and Their Implications for Mexico.Medicina (Kaunas, Lithuania) · 2026Review
- [Occult thyroid dysfunction in outpatients with liver cirrhosis].Revista medica del Instituto Mexicano del Seguro Social · 2024Article
- Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease.Hepatology forum · 2023Article
- Detangling the interrelations between MAFLD, insulin resistance, and key hormones.Hormones (Athens, Greece) · 2022Review
- COVID-19: Current Status in Gastrointestinal, Hepatic, and Pancreatic Diseases-A Concise Review.Tropical medicine and infectious disease · 2022Review
- Cirrhosis etiology trends in developing countries: Transition from infectious to metabolic conditions. Report from a multicentric cohort in central Mexico.Lancet regional health. Americas · 2022Article
- Hepatocellular Carcinoma in Mexico.Clinical liver disease · 2022Review
- Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases.Journal of clinical and translational hepatology · 2021Review
- Hepatic Dendritic Cells in the Development and Progression of Metabolic Steatohepatitis.Frontiers in immunology · 2021Review
- Article
- Awareness, Knowledge, and Misperceptions Related to Nonalcoholic Fatty Liver Disease in a Community Sample of Mexican-Origin Women: A Mixed Methods Study.Frontiers in public health · 2021Article
- Ambulatory end-stage liver disease in Ghana; patient profile and utility of alpha fetoprotein and aspartate aminotransferase: platelet ratio index.BMC gastroenterology · 2020Observational
- The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis.Annals of translational medicine · 2020Review
- The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer.Hepatoma research · 2020Article
- Epidemiology and health care burden of autoimmune liver diseases in Mexico.Clinical liver diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the main current etiologies of cirrhosis in Mexico.
methodsWe performed a cross-sectional retrospective multicenter study that included eight hospitals in different areas of Mexico. These hospitals provide health care to people of diverse social classes. The inclusion criteria were a histological, clinical, biochemical, endoscopic, or imaging diagnosis of liver cirrhosis. Data were obtained during a 5-year period (January 2012-December 2017).
resultsA total of 1210 patients were included. The mean age was 62.5 years (SD = 12.1), and the percentages of men and women were similar (52.0%
conclusionHCV and ALD are the most frequent causes of cirrhosis in Mexico. However, we note that non-alcoholic fatty liver disease (NAFLD) as an etiology of cirrhosis increased by 100% compared with the rate noted previously. We conclude that NAFLD will soon become one of the most frequent etiologies of liver cirrhosis in Mexico.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.